2seventy bio, Inc.

4.45 USD
+0.00 (+0.11%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

2seventy bio, Inc. stock is up 8.68% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 July’s closed higher than June. 0% of analysts rate it a buy.

About 2seventy bio, Inc.

2seventy bio, Inc. focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.